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obligatory IVUS or OCT guidance.
Methods: Consecutive patients with ischemic heart disease and de novo native
coronary artery lesions were enrolled at 6 German centers in the prospective,
observational registry. During the ﬁrst 6 months of enrollment, only 3.0 x 18 mm
BVS were available. From then onwards, 2.5 mm, 3.0 mm, and 3.5 mm BVS of
different length were also available. BVS sizing was based on visual estimate of
the lesions.
Results: A total of 183 patients were treated with BVS. A complex ACC/AHA
lesion morphology of B2 or C was seen in 128 (64.7%) lesions. Compared to
QCA, visual estimate overrated the baseline reference vessel diameter (RVD) by
0.5  0.5 mm and the diameter stenosis (DS) by 13.2  16.5 %. Nevertheless,
the ﬁnal minimal lumen diameter (MLD) closely matched the baseline RVD.
Diameter stenosis was 64.6  15.1% at baseline and improved to a residual DS
of 16.1  7.7%. Acute gain of MLD was 1.54  0.51 mm. A BVS-RVD
mismatch resulted in an optimal MLD but an overexpanded RVD in case of 3.0
BVS for < 2.5 mm vessels, whereas in 3.3 mm vessels ﬁnal MLD fell below the
RVD. Final RVD exceeded the BVS expansion limit in 20 (10.1%) lesions. No
periprocedural dissection was reported from the core laboratory. At 12 months, 1
(0.5%) death due to gastrointestinal bleeding under dual antiplatelet therapy and
3 (1.6%) myocardial infarctions, caused by non-target vessel failure, had
occurred. Target lesion revascularization had to be carried out in 5 patients
(2.8%).
Conclusions: Visual overestimation of baseline RVD resulted in an optimal ﬁnal
MLD. BVS-RVD mismatch may led to an inappropriate RVD or MLD. Acute
gain and frequency of MACE were in agreement with previous BVS and DES
studies.
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Background: Bioresorbable vascular scaffold (BVS) heralded as the fourth revolution
in interventional cardiology. Previous studies demonstrated the safety and efﬁcacy of
bioresorbable everolimus-eluting scaffolds in selected group of patients. However,
limited data are available on the clinical use and outcomes of BVS in the real life
setting.
Methods: Between November 2012 and April 2014, 89 consecutive patients were
treated with BVS and enrolled in a prospective single center registry. The indication of
BVS was left to the discretion of the operator.
Results: Mean age was 5911 years old and males in 69%. They had hyper-
tension in 56%, dyslipidemia in 52%, and diabetes in 29%, smokers in 48% and
known coronary artery disease in 20%. Clinical presentation was acute coronary
syndrome in 70 % of patients. Patients had a single vessel disease in 66% and the
left ventricular ejection fraction (LVEF) was 588%. One hundred sixteen le-
sions were treated (30% were type A, 62% type B and 8% type C). Average used
BVS/patient was 1.290.59. Mean BVS diameter and length were 3.10.35mm
and 225.25mm respectively. Procedural success and device success was
100%.The median follow-up was 199 days [29-365]. The in-hospital MACE rate
was low (1%; 1 case of acute deﬁnite BVS thrombosis). The cumulative mid term
MACE rate was 5 % (all cause mortality was 1% (probable BVS thrombosis); MI
1% (deﬁnite subacute BVS thrombosis) and 3% TLR (3 cases of in-BVS
restenosis).
Conclusions: In this all-comer cohort, BVS was mainly reserved to non-complex
cases and had a high acute procedural success with good mid term clinical outcomes.
Ongoing studies with long-term follow-up will conﬁrm the safety and efﬁcacy of BVS
in the treatment of more challenging cases.
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Background: The effect of mandatory non-compliant balloon(NCB) post-dila-
tion on bioresorbable vascular scaffolds(BVS) is not known. We sought toJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Steassess the impact of NCB post-dilation on optimizing BVS by using Optical
coherence tomography(OCT). We hypothesized that systematic post-dilation
to high pressures would signiﬁcantly improve expansion and reduce
malapposition.
Methods: In this ethics approved study we enrolled 18 patients. Per protocol,
mandatory pre-dilation was followed by intracoronary nitroglycerin and initial
OCT assessment. BVS was deployed at 14 atm for 30seconds and NCB post-
dilation performed at 16 atm for a minimum of 30seconds. OCT was repeated
after BVS deployment and after NCB post-dilation. All OCT images were
analyzed ofﬂine. Pre and post NCB post-dilation, the scaffold was analyzed for
minimum and mean diameters, and minimum scaffold cross-sectional area.
Optimal expansion of BVS was deﬁned as minimum scaffold area of 80% of
reference vessel area. The length of the scaffold was also assessed for clinically
relevant incomplete scaffold apposition (ISA) deﬁned as incomplete contact of
BVS struts with vessel wall for a distance of greater than the strut thickness of
0.15mm, over at least 25% of the scaffold circumference, and over a scaffold
length of at least 1mm.
Results: 22 lesions in 18 patients were analyzed. Mean patient age was 57.5yrs and
83% were male. The indication was stable angina in 83% cases. Using OCT, the
reference vessel diameter at baseline was 2.95mm. The mean BVS diameter used was
2.9mm and the mean diameter of NCB used was 3.5mm. After NCB post-dilation, the
minimum scaffold diameter increased by a mean of 0.19mm, the mean scaffold
diameter increased by a mean of 0.20mm and optimal expansion increased from 59%
to 86.4% of cases (p< 0.0001). After NCB use, clinically relevant ISA decreased from
5 to 3 cases.
Conclusions: Non-compliant balloon post-dilation of BVS signiﬁcantly increased the
minimum and mean scaffold diameter. The rate of optimal scaffold expansion
increased by 27%, and the incidence of clinically relevant incomplete scaffold
apposition decreased by 40%.
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Background: Patient reported outcomes (PROs) are increasingly recognized as
important clinical trial endpoints that provide direct information about health
status and help guide clinical and economic decisions. Prior studies have re-
ported quality of life (QoL) decrements attributable to changes in angina status.
The objective of this study was to assess the impact of changes in angina status
following percutaneous coronary intervention (PCI) on QoL in ABSORB II, a
randomized, controlled, multicenter trial that compared the safety and efﬁcacy
of the Absorb Bioresorbable Vascular Scaffold (Abbott Vascular, Santa
Clara, CA) to the XIENCE Everolimus Eluting Stent (Abbott Vascular, Santa
Clara, CA).
Methods: In the ABSORB II trial, we obtained disease-speciﬁc QoL and general
health status information from patients using validated PRO instruments admin-
istered pre-intervention, at 6 months, and 1 year post-discharge. We examined the
timing of changes in angina status in relation to the assessment date of the
EuroQol-5 Dimension Questionnaire (EQ-5D). We compared means and conﬁ-
dence intervals of subjects with changes in angina status within 1 month, 1-3
months, and greater than 3 months prior to assessment. A similar analysis was
conducted for the Seattle Angina Questionnaire (SAQ). Multivariate analysis was
performed to control for observable patient characteristics that might inﬂuence
QoL.
Results: The ABSORB II trial enrolled 501 patients at 46 sites in Europe and New
Zealand and randomized in a 2:1 ratio to Absorb BVS (N¼335) or XIENCE
(N¼166). We will present results of the univariate and multivariate analyses in the
ABSORB II intent-to-treat population.
Conclusions: Research to date indicates that changes in angina status are indepen-
dently associated with reduced QoL. Results from the ABSORB II trial will provide
current evidence of the impact of changes in angina status on QoL following PCI with
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